Global Neurovascular Thrombectomy Devices Market 2023: Ischemic Stroke to drive the expansion of market

The latest research report by Persistence Market Research (PMR), a well-known name in market research, states that the Neurovascular Thrombectomy Devices Market will witness a CAGR of 6.40% from 2022 to 2026, and will exceed USD 841.2 million in the market value by the end of 2026. The growing incidence of ischemic stroke is projected to boost the growth of the Global Neurovascular Thrombectomy Devices Market. As per the Centers for Disease Control and Prevention (CDC) in the United States, ischemic strokes account for almost 87% of all the strokes and are a primary cause of long-term impairment. It is anticipated that such stroke occurrences would increase in the years to come. This factor is expected to drive the growth of the Global Neurovascular Thrombectomy Devices Market.

Request For Free Sample Report of "Neurovascular Thrombectomy Devices Market"@ https://www.persistencemarketresearch.com/samples/26176

The Impact of COVID-19 on the Neurovascular Thrombectomy Devices Market

Even though the COVID-19 has affected various healthcare operations, the Neurovascular Thrombectomy Devices Market has grown rapidly. The increased risk of thromboembolism among COVID-19 patients drove up demand for thrombectomy treatments, increasing market revenue.

Companies

Medtronic Plc
Stryker Corporation
Teleflex Incorporated
Terumo Corporation
Johnson & Johnson Services, Inc.
Penumbra Inc.
Boston Scientific Corporation
Edwards Lifesciences Corporation
Acandis GmbH
Argon Medical Inc

Competitive Landscape

Neurovascular Thrombectomy Devices industry is very competitive and highly consolidated due to the presence of several large players. Key players in the neurovascular thrombectomy devices market are focusing on acquiring companies in order to increase their product offerings and gain a larger share of the global neurovascular thrombectomy devices market in terms of revenue.

NeuroVasc Technologies, Inc. treated the first patient in a Chinese Pivotal Randomized Controlled Trial to evaluate the safety and efficacy of the ENVITM-SR Mechanical Thrombectomy System (ENVITM-SR), a stent-retriever for the removal of blood clots in patients with acute ischemic stroke due to large vessel occlusion, in September 2021.
Terumo Medical Corporation (TMC) announced the launch of the AZUR Vascular Plug in July 2021. It is the first and only plug that can occlude arteries up to 8mm in diameter using a microcatheter. Such advanced product launches aided the company's market position.
Per-flow Medical, a private, Israeli-based neurovascular treatment innovator, achieved the first successful clinical usage of the StreamTM17 Dynamic Neuro-Thrombectomy Net, a lower profile device designed for more tortuous anatomy, to effectively treat hemorrhagic and ischemic stroke patients in April 2021.

Buy Full Report Now @ https://www.persistencemarketresearch.com/checkout/26176

North America is projected to have a sizable market share

The increasing prevalence of acute ischemic strokes, extensive research, enhanced product launches, and rising strategic initiatives by leading market players are the primary driving factors for the growth of the North American Neurovascular Thrombectomy Devices Market. Because of the high prevalence of stroke, the U.S. is likely to occupy a considerable proportion of the market over the forecast period. Furthermore, increased investments will enhance market innovation, consequently boosting the market growth.

In addition, rising Asia-Pacific countries such as China and India are likely to emerge as new revenue-generating markets. The existence of a large patient pool for target illnesses increased awareness among surgeons about the advantages of Neurovascular Thrombectomy Devices, increased healthcare expenditure, and increased use of these devices, all contribute to the growth of this Asia-Pacific's market.

Want More Insights?

PMR has presented a comprehensive report based on Neurovascular Thrombectomy Devices Market as per Product Type (Stent Retriever and Aspiration Catheter), End User (Hospitals, Neuro-Catheterization Labs and Specialized Neurosurgery Centers) based on seven regions.

Request Customization @ https://www.persistencemarketresearch.com/request-customization/26176

Key Questions Answered in This Report.

What are the Roadblocks for Neurovascular Thrombectomy Devices Market Suppliers?
What are the Key Opportunities for Neurovascular Thrombectomy Devices Market Manufacturers?
How is Focus on Safety Influencing Neurovascular Thrombectomy Devices Market Demand?
What is the Regulatory Impact on Global Sales of Neurovascular Thrombectomy Devices Market?
Which Region Offers the Largest Opportunity for Sales of Neurovascular Thrombectomy Devices Market?
Where Does the U.S. Stand in the Market for Neurovascular Thrombectomy Devices Market?
What Is the Outlook for Neurovascular Thrombectomy Devices Market Manufacturers in China?
Why is Germany a Lucrative Market for Neurovascular Thrombectomy Devices Market Manufacturers?
Why Will Belgium Outpace Other European Markets for Neurovascular Thrombectomy Devices Market?
Why is There High Demand for Tires in Neurovascular Thrombectomy Devices Market?
Why are Sales of Neurovascular Thrombectomy Devices Market Surging?

Media Contact:
Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353
sales@persistencemarketresearch.com

About Us

Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

This release was published on openPR.